Department of Immunobiology, Yale University, New Haven, Connecticut.
Division of Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Cancer Discov. 2021 Jul;11(7):1700-1715. doi: 10.1158/2159-8290.CD-20-0962. Epub 2021 Mar 3.
Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non-small cell lung cancer (NSCLC). We identified a burned-out CD8 TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8 TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. SIGNIFICANCE: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8 tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker..
肿瘤浸润淋巴细胞(TIL)功能失调的具体机制仍知之甚少。在这里,我们采用了一种双管齐下的方法,使用单细胞质谱流式细胞术和组织成像技术从 25 名可切除和 35 名晚期非小细胞肺癌(NSCLC)患者中分离 TIL。我们鉴定了一种功能失调的耗尽型 CD8 TIL 亚群(Ebo),该亚群特异性地在肿瘤微环境(TME)中积累,但不在相邻的非肿瘤组织中积累。Ebo 表现出最高的增殖和激活标志物表达,但产生的 IFNγ 最少,是最凋亡的 CD8 TIL 亚群。使用人源化患者来源的肿瘤异种移植模型,我们证明 Ebo 的扩增发生在 PD-1/B7-H1 通路依赖性的 TME 内。基线肿瘤组织中 Ebo 的丰度与 NSCLC 患者对抗 PD 治疗的耐药性相关。我们的研究鉴定了一种功能失调的 TIL 亚群,与先前描述的耗竭性 T 细胞具有不同的特征,并暗示了克服免疫治疗耐药性的策略。意义:我们鉴定了一种高度增殖、过度激活和凋亡的功能失调的 CD8 肿瘤浸润亚群,与先前描述的耗竭性 T 细胞在功能上不同。该群体在 PD-1/B7-H1 依赖性方式在肺癌组织中扩增,其丰度与癌症免疫治疗的耐药性相关,因此成为一种潜在的组织生物标志物。